Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Qureight, a UK-based imaging company that's carved out a niche in lung and heart disease trials, has closed a $20 million Series B led by Molten Ventures. Existing backers Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension all came back for another round, pushing the company's total funding past €27 million.

The money is going toward something Qureight calls an AI imaging laboratory, built around a 3D chest imaging foundation model. The pitch is straightforward: less data, less time, faster disease models. That matters in clinical trials, where imaging analysis can be a bottleneck that adds months or years to getting a drug to market.

Qureight's platform already does a lot. It runs imaging CRO services that help trial sites onboard faster and make better patient inclusion calls. It has proprietary AI biomarkers that measure structural changes in lung tissue, tracking disease progression compartment by compartment. And it offers synthetic control arms, letting companies compare results against a virtual arm instead of running a full parallel study, which trims both cost and duration.

Up to now, the company's stronghold has been fibrotic lung diseases, where its models are already embedded with biopharma partners doing real-time trial work. This raise is meant to push that expertise into asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity, four areas where demand for sharper imaging analytics in trial design is climbing but tools remain thin.

CEO Muhunthan Thillai framed the round as validation of Qureight's platform and team, welcoming Molten's Inga Deakin and Hargreave Hale's Anna Salim to the board. Deakin, for her part, described Qureight as proof that AI paired with real-world data can speed up medical discovery, calling out the company's ability to move fast into underserved corners of clinical research.